Citations with the tag: SCHIZOPHRENIA -- Treatment
Results 1 - 50
- Balancing hope with safety.
Folkenberg, Judy // FDA Consumer; Jun90, Vol. 24 Issue 5, p16
Reports how Clozaril, a new antipsychotic drug, can help thousands of the most seriously afflicted schizophrenics function well enough to leave mental hospitals. But it also can cause a serious blood disorder. INSET: A psychiatric mystery, by J.F..
- Treatment resistance in schizophrenia.
Johnston, Eve C.; Sandler, Robert // BMJ: British Medical Journal (International Edition); 2/10/96, Vol. 312 Issue 7027, p325
Focuses on the use of alternative drugs in treating schizophrenia. Functions of chlorpromazine; Use of functional imaging techniques in schizophrenia.
- Cognitive improvement is possible for schizophrenic patients.
Spaulding, William D. // Behavioral Health Treatment; Oct96, Vol. 1 Issue 4, p3
Asserts that cognitive improvement is possible for schizophrenic patients in the United States. Results of re-examination of old assumptions concerning schizophrenia; Clinical manifestations of the ailment; Advances in neuropsychology.
- Early relapse may result from neuroleptic withdrawal.
Spaulding, William D. // Behavioral Health Treatment; Jun97, Vol. 2 Issue 6, p5
States that persons with schizophrenia who are abruptly withdrawn from neuroleptics may be twice as likely to suffer relapses within six months. Information on the study which provided the evidence; Details on the findings of the study.
- Fish oil may relieve schizophrenia symptoms.
Spaulding, William D. // Behavioral Health Treatment; Oct97, Vol. 2 Issue 10, p3
Presents information on a study which examined ways to reduce the symptoms associated with schizophrenia. Information on fish oil and how it can be used as a treatment for certain schizophrenic symptoms; Identification of countries in which research is being carried out; Details on side effects...
- Healing without hurting the troubled mind.
Bradley, David // New Scientist; 9/12/92, Vol. 135 Issue 1838, p18
Reveals that a drug candidate that could treat the symptoms of schizophrenia without causing the debilitating side-effects of traditional drugs has been developed by chemists in the United States. Compound is named HP 236; Could replace the drug clozapine; Background of the disorder.
Paltak, Margie // FDA Consumer; Sep/Oct97, Vol. 31 Issue 6, p23
Scrutinizes schizophrenia, a mental illness. Causes and symptoms of schizophrenia; Characteristics of a schizophrenic; Development of antipsychotic medications and their side effects; Other treatment for schizophrenia.
- A new antipsychotic agent with dual benefits.
Cerrato, Paul L. // RN; Feb98, Vol. 61 Issue 2, p71
Presents information on quetiapine (Seroquel) which was approved by the United States Food and Drug Administration for treating schizophrenia and other psychotic disorders. Side effects of the drug.
- APA practice guideline for the treatment of patients with...
Rose, Verna L. // American Family Physician; 9/15/1997, Vol. 56 Issue 4, p1217
Provides guidelines for the treatment of patients with schizophrenia issued by the American Psychiatric Association (APA). Eight main sections of the guideline; List of conventional antipsychotic drugs in the guideline; Coverage and features of the guideline.
- Drug treatment of schizophrenia.
Walling, Anne D. // American Family Physician; 4/15/1998, Vol. 57 Issue 8, p1998
Presents the summary `Drug treatment of schizophrenia,' which can be found in The Practitioner dated January 1998.
- Kayo chaos.
Portyansky, Elena // Drug Topics; 10/20/97, Vol. 141 Issue 20, p32
Focuses on a drug called Seroquel (quetiapine fumarate), which was approved for the treatment of schizophrenia. Drug developed by Zeneca Pharmaceuticals; Efficacy and tolerability profile of the drug; Warning that quetiapine could result in the possible emergence of tardive dyskinesia.
- Clinical Manual for Treatment of Schizophrenia.
Mairs, Hilary // Mental Health Practice; Mar2013, Vol. 16 Issue 6, p8
No abstract available.
Mairs, Hilary // Canadian Journal of Psychiatry; Nov98 Supplement, Vol. 43, p38s
A variety of algorithms, forms and other clinical aids related to articles that appeared in the November 1998 issue of -The Canadian Journal of Psychiatry- is presented.
Mairs, Hilary // Canadian Journal of Psychiatry; Nov98 Supplement, Vol. 43, following p39s
A list of articles on schizophrenia published in several journals is presented, including "The Expert Consensus Guidelines Series: The Treatment of Schizophrenia," by A. Frances, J. P. Docherty and D. A. Kahn, and "Reasons for Substance Abuse in Schizophrenia," by J. Addington and V. Duchak.
- Risperidone for Insomnia in PDDs.
Doan, Richard J. // Canadian Journal of Psychiatry; Dec98, Vol. 43 Issue 10, p1050
A letter to the editor is presented in response to the topic on risperidone for insomnia in pervasive developmental disorders.
- OLANZAPINE-INDUCED OCULOGYRIC CRISIS IN A PATIENT WITH SCHIZOPHRENIA.
Chakraborty, Rudraprosad; Chatterjee, Arunima; Chaudhury, Suprakash // Indian Journal of Medical Sciences; Jun2008, Vol. 62 Issue 6, p238
A letter to the editor is presented concerning a 25-year old man with schizophrenia for 6 months, and initially treated with 8 milligrams of risperidone per day and 40 milligrams of fluoxetine per day.
- AMISULPRIDE-INDUCED BOTH OCULOGYRIC CRISIS AND TRISMUS.
Mendhekar, D. N.; Yajuvendra, Bisht; Aggarwal, Ashish // Indian Journal of Medical Sciences; Jun2008, Vol. 62 Issue 6, p239
A letter to the editor is presented concerning the case of a 24-year old male with schizophrenia and treated with amisulpride.
- Economic evaluations of olanzapine and risperidone.
Shaw, James W. // American Journal of Health-System Pharmacy; 7/15/2002, Vol. 59 Issue 14, p1366
Presents an economic analysis comparing olanzapine and risperidone for treating schizophrenia. Overview of the disease; Costs of schizophrenia; Methods of economic evaluation; Results of randomized clinical trials.
Winans, Elizabeth // American Journal of Health-System Pharmacy; 12/1/2003, Vol. 60 Issue 23, p2437
Discusses the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions and dosage and administration of aripiprazole, an antipsychotic agent indicated for treating schizophrenia. Oral availability; Adverse effects; Recommended starting dosage.
- New schizophrenia drugs could be worth their cost.
Carrell, Steve // Drug Topics; 5/6/96, Vol. 140 Issue 9, p80
Discusses the economic aspects of the use of drugs such as sertindole and olanzapine in the treatment of schizophrenia. Economic analysis of the drugs according to the book `Handbook of Mental Health Economics and Health Policy'; Expenses related to schizophrenia; Incidence of the ailment in the...
- Treating schizophrenia: New strategies.
Williamson, John S.; Wyandt, Christy M. // Drug Topics; 11/6/2000, Vol. 144 Issue 21, p64
No abstract available.
- Managing schizophrenia under new guidelines.
McWilliam, Chris // Pulse; 10/28/2002, Vol. 62 Issue 41, p40
Provides an overview of schizophrenia management in the light of the British government's guidelines on atypical neuroleptics. Types of schizophrenic patients requiring different support links and secondary care services; Etiology of the disease.
- Atypical neuroleptics are the greatest schizophrenia breakthrough in 10 years.
McWilliam, Chris // Pulse; 10/28/2002, Vol. 62 Issue 41, p42
Focuses on the development of atypical neuroleptics for the treatment of schizophrenia in Great Britain. Mode of action; Interaction with serotonin and dopamine pathways in the brain; British government's guidelines on the use of atypicals.
- Relapsing schizophrenic wants diazepam.
McWilliam, Chris // Pulse; 11/11/2002, Vol. 62 Issue 43, p32
Presents several treatment options from physicians for a relapsing schizophrenic patient in Great Britain. Emphasis on controlling patient's addiction to diazepam; Reintroduction of home treatment team to monitor the mental status of the patient; Use of diazepam as a bargaining tool to enhance...
- Red tape eliminated, drug now available to help mentally ill.
McWilliam, Chris // New York Amsterdam News; 3/23/96, Vol. 87 Issue 12, p12
Reports that in New York City, Governor George Pataki authorized the usage of the drug Clozapine, for Medicaid patients suffering from schizophrenia. How the drug helps schizophrenics; Why the drug was curtailed; Comments from Pataki.
Luisi, Andrea F. // Formulary; Nov2002, Vol. 37 Issue 11, p575
Discusses aripiprazole, an antipsychotic used for the treatment of schizophrenia. Mechanism of action; Pharmacology; Effectiveness; Pharmacokinetics. INSET: Formulary considerations.
- Combined (Individual and Group) Psychodynamic Psychotherapy in the Rehabilitation of Schizophrenic Patients.
Guseva, O.V.; Iovlev, B.V.; Shchelkova, O.Iu. // International Journal of Mental Health; Summer2002, Vol. 31 Issue 2, p61
Investigates the efficacy of combined psychodynamic psychotherapy in the rehabilitation of schizophrenic patients. Effectiveness of specific psychotherapy treatment; Selection of experimental-psychological methods adequate for the revelation of the dynamics of psychological parameters in...
- Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia.
Wiedemann, G.; Hahlweg, K.; M�ller, U.; Feinstein, E.; Hank, G.; Dose, M. // European Archives of Psychiatry & Clinical Neuroscience; 2001, Vol. 251 Issue 2, p72
Abstract A sample of 85 patients with schizophrenia, of whom 34 later dropped out, received randomised treatment. There were no significant differences between treatment-takers and drop-outs in the variables assessed. Patients received either standard-dose maintenance neuroleptic treatment or...
- A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia.
Albus, Margot; Hubmann, Werner; Scherer, Josef; Dreikorn, Bettina; Hecht, Susanne; Sobizack, Norbert; Mohr, Fritz // European Archives of Psychiatry & Clinical Neuroscience; 2002, Vol. 252 Issue 6, p262
To investigate the temporal stability, or progressivity, of neuropsychological (NP) impairment in schizophrenia, 50 patients with first episode (FE) schizophrenia and 50 healthy controls were given a battery of tests at the outset of the study and after a two-year interval. Both patient and...
- Neuropsychological Therapeutic Community Treatment for Individuals with Schizophrenia.
Miran, Michael D.; Miran, Esta R. // Psychiatric Rehabilitation Journal; Winter99, Vol. 22 Issue 3, p277
Describes the theoretical basis and treatment procedures of a neuropsychological therapeutic community approach to the treatment of individuals with schizophrenia. Presentation of the five-step treatment approach; Role of families in the treatment process; Organization and administration of the...
- An Approach to the Understanding of 'Schizophrenese'
Mosak, Harold H.; Maniacci, Michael P. // Individual Psychology: The Journal of Adlerian Theory, Research ; Dec89, Vol. 45 Issue 4, p465
Focuses on the conceptualization of schizophrenia disease. Symptoms of the disease; Guidelines for working psychotic populations; Importance of phenomenological perspective toward the treatment and understanding of schizophrenia.
- Treatment alliance and the chronic schizophrenic.
Selzer, Michael A.; Carsky, Monica // American Journal of Psychotherapy; Oct1990, Vol. 44 Issue 4, p506
Describes ways a psychotherapist can facilitate a sense of relatedness with the schizophrenic patient. Therapist's identification and joining with the part of the patient which is in conflict with his psychosis; Role of the techniques in allowing the patient to identify with and introject...
- Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations.
Llorca, Pierre-Michel; Lancon, Christophe; Disdier, Beatrice; Farisse, Jean; Sapin, Christophe; Auquier, Pascal // Journal of Psychiatry & Neuroscience; Jan2002, Vol. 27 Issue 1, p30
Evaluates the effectiveness of clozapine in neuroleptic-resistance schizophrenia, in terms of its clinical response and plasma concentrations. Mean endpoint clozapine dosage; Significant correlation found between the daily dosage of clozapine and the plasma levels of clozapine and of its...
- Psychopharmacology for the Clinician.
Prior, Trevor I. // Journal of Psychiatry & Neuroscience; May2002, Vol. 27 Issue 3, p224
Focuses on the pharmacologic management of patients with schizophrenia using clozapine. Side effects of clozapine; Role of cytochrome P450 enzymes in the mechanisms of side effects; Determination on the therapeutic serum levels of the drug.
- Curtain on Schizophrenia: A Twenty-five-Year Clinical Follow-up.
Betz, Barbara J. // American Journal of Psychotherapy; Apr1980, Vol. 34 Issue 2, p252
Reports on a 25-year clinical study of an individual patient's emergence from severe chronic schizophrenia. Demonstration of techniques to find ways around the basic schizophrenic instability; Description of the frame within which such a happening can follow.
- Individual Psychotherapy in the Treatment of Chronic Schizophrenic Patients.
Cancro, Robert // American Journal of Psychotherapy; Oct1983, Vol. 37 Issue 4, p493
Presents the author's views on process and personal characteristics which are important to the use of psychotherapy in treating schizophrenia. Details of the historical background in the application of psychotherapy for schizophrenics; Comparison with its effectiveness with pharmacotherapy.
- Psychological Medicine.
Kennedy, P.F. // British Medical Journal; 5/3/1975, Vol. 2 Issue 5965, p257
Investigates the treatment of schizophrenia and related paranoid psychoses in Great Britain. Symptoms of schizophrenia; Prevalence of paranoid state in older patients; Relationship between schizophrenia and paranoid psychoses.
- Benefits of Switching From Typical to Atypical Antipsycholtic Medications: A Longitudinal Study in a Community-Based Setting.
Cook, Peter E; Goldberg, Joel O; Van Lieshout, Ryan J // Canadian Journal of Psychiatry; Nov2002, Vol. 47 Issue 9, p870
Objective: This study examines the clinical and resource utilization effects of switching stable outpatients with schizophrenia from a typical to an atypical antipsychotic medication. Method: We monitored 43 schizophrenia patients from a Community mental health program who tolerated switching...
- Gabapentin-Induced Paradoxical Exacerbation of Psychosis in a Patient With Schizophrenia.
Cook, Peter E; Goldberg, Joel O; Van Lieshout, Ryan J // Canadian Journal of Psychiatry; Dec2002, Vol. 47 Issue 10, p975
Focuses on the role of anticonvulsant, gabapentin, induced by paradoxical exacerbation of psychosis in a patient with schizophrenia. Effects of gabapentin on patients; Psychotic symptoms of the disease; Mechanisms to explain the effect of gabapentin on patients.
- Therapeutic Drug Monitoring: Chemical-Clinical Correlations of Atypical Antipsychotic Drugs.
Raggi, M.A. // Current Medicinal Chemistry; Jul2002, Vol. 9 Issue 14, p1397
In the last few years, new drugs for the treatment of schizophrenia have been introduced in therapy which have noticeably improved the quality of life of many schizophrenic patients. These new ï¿½atypicalï¿½ drugs have chemical, pharmacological and clinical properties which are different...
- Benefits and Limitations of Neuroleptics--and Other Forms of Treatment--in Schizophrenia.
Marder, Stephen R.; May, Philip R.A. // American Journal of Psychotherapy; Jul1986, Vol. 40 Issue 3, p357
Presents a review, by the authors, of the limitations and the benefits of neuroleptic drugs. How the drugs used to treat schizophrenics are limited by side effects.
- Future of the Chronic Schizophrenic Patient: Prediction and Recommendations.
Gralnick, Alexander // American Journal of Psychotherapy; Jul1986, Vol. 40 Issue 3, p418
Presents an historical sketch of psychiatry and the many factors which finally led from the zenith of the state hospital system in the 1940s to the deinstitutionalization process and its consequences in the U.S. Predictions about the future diagnosis, care and treatment of schizophrenic...
- Profiling of CSF: Small Subgroups.
Hambridge, Dave // PLoS Medicine; Oct2006, Vol. 3 Issue 10, p1973
A letter to the editor is presented about the treatment of schizophrenia.
- Letters to the Editor.
Unger, Nathan; Addington, Donald // Canadian Journal of Psychiatry; Sep2012, Vol. 57 Issue 9, p583
A letter to the editor is presented in response to the article "Conformance to evidence-based treatment recommendations in schizophrenia treatment services," by Addington D, McKenzie E and Smith H which also includes a response by the author of the article.
- Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil, Sandeep T; Zhang, Lu; Martenyi, Ferenc; Lowe, Stephen L; Jackson, Kimberley A; Andreev, Boris V; Avedisova, Alla S; Bardenstein, Leonid M; Gurovich, Issak Y; Morozova, Margarita A; Mosolov, Sergey N; Neznanov, Nikolai G; Reznik, Alexander M; Smulevich, Anatoly B; Tochilov, Vladimir A; Johnson, Bryan G; Monn, James A; Schoepp, Darryle D // Nature Medicine; Oct2007, Vol. 13 Issue 10, p1264
A correction to the article "Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial" that was published in the September, 2007 issue is presented.
- Relatives and patients as partners in the management of...
Birchwood, Max; Smith, Jo // Psychosocial Rehabilitation Journal; Jan90, Vol. 13 Issue 3, p27
Highlights the integration of family management of schizophrenia into clinical practice. Challenges faced by rehabilitation professionals involved in developing clinical services; Information on the problem of engagement; Description of the heavy demands on mental resources as a result of...
- A large-scale field test of a medication management skills...
Eckman, Thad A.; Liberman, Robert P. // Psychosocial Rehabilitation Journal; Jan90, Vol. 13 Issue 3, p31
Focuses on a field test study of the utility and efficacy of a medication program at the the University of California (UCLA) Clinical Research Center. Methods employed in study; Danger of failure to adhere to prescribed drugs, with reference to patients with chronic schizophrenic; Number of...
- Psychotherapy with schizophrenics in team groups: A systems model.
Beeber, Alan R. // American Journal of Psychotherapy; Jan1991, Vol. 45 Issue 1, p78
Focuses on the treatment of schizophrenia using the team group model of psychotherapy. Description of the team group model; Advantages and disadvantages of the model; Treatment approaches; Systems approach incorporating principles of group development; Problems encountered in treating patients...
- Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia.
Beeber, Alan R. // Evidence Based Mental Health; Nov2009, Vol. 12 Issue 4, p112
An abstract of the article "Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia," by C. Barbui and colleagues is presented.
- Anxiogenic, not psychotogenic, properties of the partial inverse benzodiazepine receptor agonist FG 7142 in man.
Horowski, R.; Dorow, R. // Psychopharmacology; 2002, Vol. 162 Issue 2, p223
Proposes the application of FG 7142, the first benzodiazepine receptor partial inverse agonist, as an alternative psychotogenic manipulation for studying cortical and cognitive aspects of schizophrenia. Side effects of the FG 7142; Description of patients on the experience using the substance;...